FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892133080> ?p ?o ?g. }

• W2892133080 endingPage "11558" @default.
• W2892133080 startingPage "11558" @default.
• W2892133080 abstract "11558 Background: Radiation therapy (RT) is an integral part of the treatment of breast carcinoma but unfortunately many patients experience local recurrence. During the inflammatory response that accompanies radiation tumor cells may develop multiple resistance mechanisms for example the up-regulation of PD-L1 on tumor cells which leads to immune evasion. Since CETCs arise from the tumor it is conceivable that under evolutionary pressure they might share some of the immune escape mechanism inherent to tumor cells. In this study we demonstrate that RT leads to a transitory adaptive up-regulation of PD-L1 expression on CETCs. Methods: CETCs and the expression of PD-L1 and Ki-67 were analyzed from 25 patients with primary non-metastatic breast cancer using the maintrac method. The fraction of PD-L1 and Ki-67 positive CETCs were assessed at baseline, 3 and 6 weeks after start of RT and 6 weeks after end of therapy. Additionally, copy number status of PD-L1 was determined using FISH. Results: Fractionated-dose RT leads to a significant increase in PD-L1 expression on CETCs with the highest expression level midterm of irradiation as compared to baseline (49% vs. 74%, p < 0.01). 6 weeks after end of RT the number of PD-L1 positive CETCs returned to baseline value. The up-regulation of PD-L1 was dose dependent. Patients who received higher total dose had significantly more PD-L1 positive CETCs as compared to patients treated with lower total dose midterm of RT (64% vs. 43, p < 0.05). Before start of therapy there was a correlation between the fraction of PD-L1 and Ki-67 positive CETCs (r = 0.6, p < 0.01). PD-L1 copy number gains were significantly associated with PD-L1 expression (r = 0.6, P < 0.05). Conclusions: RTleads to an up-regulation of PD-L1 expression on CETCs, which could be a possible mechanism of acquired radioresistance. Combining immunomodulatory agents with radiation might have the potential to overcome this resistance and could improve clinical outcome in breast cancer." @default.
• W2892133080 created "2018-09-27" @default.
• W2892133080 creator A5014924069 @default.
• W2892133080 creator A5050886792 @default.
• W2892133080 creator A5063234663 @default.
• W2892133080 creator A5064184590 @default.
• W2892133080 creator A5083075658 @default.
• W2892133080 date "2017-05-20" @default.
• W2892133080 modified "2023-10-17" @default.
• W2892133080 title "Adjuvant radiation therapy to induce a transitory adaptive up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) to affect the anti-tumor immune response in primary breast cancer patients." @default.
• W2892133080 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11558" @default.
• W2892133080 hasPublicationYear "2017" @default.
• W2892133080 type Work @default.
• W2892133080 sameAs 2892133080 @default.
• W2892133080 citedByCount "0" @default.
• W2892133080 crossrefType "journal-article" @default.
• W2892133080 hasAuthorship W2892133080A5014924069 @default.
• W2892133080 hasAuthorship W2892133080A5050886792 @default.
• W2892133080 hasAuthorship W2892133080A5063234663 @default.
• W2892133080 hasAuthorship W2892133080A5064184590 @default.
• W2892133080 hasAuthorship W2892133080A5083075658 @default.
• W2892133080 hasConcept C121608353 @default.
• W2892133080 hasConcept C126322002 @default.
• W2892133080 hasConcept C143998085 @default.
• W2892133080 hasConcept C203014093 @default.
• W2892133080 hasConcept C2777701055 @default.
• W2892133080 hasConcept C2777863537 @default.
• W2892133080 hasConcept C2779013556 @default.
• W2892133080 hasConcept C2780283643 @default.
• W2892133080 hasConcept C2781053074 @default.
• W2892133080 hasConcept C502942594 @default.
• W2892133080 hasConcept C509974204 @default.
• W2892133080 hasConcept C530470458 @default.
• W2892133080 hasConcept C71924100 @default.
• W2892133080 hasConcept C8891405 @default.
• W2892133080 hasConceptScore W2892133080C121608353 @default.
• W2892133080 hasConceptScore W2892133080C126322002 @default.
• W2892133080 hasConceptScore W2892133080C143998085 @default.
• W2892133080 hasConceptScore W2892133080C203014093 @default.
• W2892133080 hasConceptScore W2892133080C2777701055 @default.
• W2892133080 hasConceptScore W2892133080C2777863537 @default.
• W2892133080 hasConceptScore W2892133080C2779013556 @default.
• W2892133080 hasConceptScore W2892133080C2780283643 @default.
• W2892133080 hasConceptScore W2892133080C2781053074 @default.
• W2892133080 hasConceptScore W2892133080C502942594 @default.
• W2892133080 hasConceptScore W2892133080C509974204 @default.
• W2892133080 hasConceptScore W2892133080C530470458 @default.
• W2892133080 hasConceptScore W2892133080C71924100 @default.
• W2892133080 hasConceptScore W2892133080C8891405 @default.
• W2892133080 hasIssue "15_suppl" @default.
• W2892133080 hasLocation W28921330801 @default.
• W2892133080 hasOpenAccess W2892133080 @default.
• W2892133080 hasPrimaryLocation W28921330801 @default.
• W2892133080 hasRelatedWork W2163676795 @default.
• W2892133080 hasRelatedWork W2904993668 @default.
• W2892133080 hasRelatedWork W2972384824 @default.
• W2892133080 hasRelatedWork W3009386543 @default.
• W2892133080 hasRelatedWork W3030741499 @default.
• W2892133080 hasRelatedWork W3180780036 @default.
• W2892133080 hasRelatedWork W4291367166 @default.
• W2892133080 hasRelatedWork W4322772323 @default.
• W2892133080 hasRelatedWork W4360983034 @default.
• W2892133080 hasRelatedWork W68488667 @default.
• W2892133080 hasVolume "35" @default.
• W2892133080 isParatext "false" @default.
• W2892133080 isRetracted "false" @default.
• W2892133080 magId "2892133080" @default.
• W2892133080 workType "article" @default.